The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

Myasthenia gravis is a serious, rare, and chronic neuromuscular autoimmune disease that can cause debilitating and potentially life-threatening muscle weakness ... two phase 3 studies in relapsing ...

Guillain-Barré Syndrome (GBS) poses a diagnostic challenge due to its misleading symptoms, the lack of a definitive test, and ...

In this study ... no evidence of muscle atrophy, fatty infiltration, or changes in muscle signal. According to the diagnosis criteria of International Consensus Guidance for Management (5), the final ...

Emerging evidence suggests that myasthenia gravis (MG) may also play a role in post-stroke fatigue, offering a new perspective on patient management and long-term disability reduction. Objectives: ...

MNDs are neurological disorders that destroy motor neurons, the cells that control skeletal muscle activity such as walking, breathing, speaking, and swallowing.

Large-scale studies ... findings. Myasthenia gravis (MG) is an autoimmune disease affecting the neuromuscular junction; it is primarily caused by the production of anti-acetylcholine receptor ...